Every material Form 8-K Korsana Biosciences, Inc. has filed with the SEC since August 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Korsana Biosciences reported its third quarter 2026 results on November 5, 2026, with a net loss of $46.4 million, up from $21.7 million a year earlier, as research and development expenses rose to $42.1 million. The company completed its merger with Cyclerion Therapeutics and a concurrent $380 million private placement in September 2026, and had $456.2 million in cash and cash equivalents at September 30, 2026, which it expects to fund operations into 2029.
Net loss of $46.4 million for Q3 2026, versus $21.7 million in Q3 2025; net loss per common share of $3.19, versus $39.49 a year earlier
R&D expenses of $42.1 million and G&A expenses of $6.1 million for Q3 2026
Cash and cash equivalents of $456.2 million at September 30, 2026, expected to fund operations into 2029
KRSA-028 Phase 1 healthy volunteer data expected in mid-2027; preclinical poster scheduled for November 18, 2026 at CTAD 2026
Korsana Biosciences completed its merger with Cyclerion Therapeutics on September 8, 2026, and the combined company is set to trade on Nasdaq under the ticker KRSA starting September 9. The closing included a $380 million private placement and a 1-for-7 reverse split of Cyclerion common stock, leaving about 55.1 million shares and share equivalents outstanding, excluding equity awards. The company expects pro-forma cash of about $475 million to fund operations into 2029, but it reported a $30.9 million net loss for the six months ended June 30, 2026.
Merger closed September 8, 2026; shares begin trading on Nasdaq as KRSA on September 9, 2026
$380 million gross proceeds from a private placement led by Fairmount and Venrock Healthcare Capital Partners
About 55.1 million shares and share equivalents outstanding after closing, excluding equity awards
Pro-forma cash of about $475 million, expected to fund operations into 2029; net loss of $30.9 million for the six months ended June 30, 2026
Cyclerion shareholders approved the share issuance tied to the Merger, a 1-for-7 reverse stock split, and an increase in authorized shares to 700,000,000 at a meeting on August 26, 2026. They did not approve the proposal to move the company's domicile to the Cayman Islands, so the combined company will remain a Massachusetts corporation. The Cayman move was not a condition to closing the Merger.
Reverse stock split of 1-for-7 approved with 3,877,744 votes for and 18,003 against; the combined company is expected to trade as KRSA on Nasdaq at the open on September 9, 2026
Merger-related Nasdaq stock issuance approved with 3,392,645 votes for and 3,730 against
Redomestication to the Cayman Islands not approved: 2,099,051 for and 1,296,575 against, short of the required vote
Quorum was 3,896,779 of 4,681,351 shares entitled to vote, based on the July 17, 2026 record date
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Korsana Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →